Flow cytometric assessment of circulating platelet and erythrocytes microparticles in young thalassemia major patients: Relation to pulmonary hypertension and aortic wall stiffness

European Journal of Haematology

Volumn 90, Issue 6, 2013, Pages 508-518

  Tantawy, Azza A G ^a   Adly, Amira A M ^a   Ismail, Eman A R ^a   Habeeb, Nevin M ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Aortic stiffness; Microparticles; Pulmonary hypertension; Thalassemia

Indexed keywords

D DIMER; FERRITIN; HEMOGLOBIN; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; ARTERIAL STIFFNESS; ARTICLE; BLOOD VESSEL COMPLIANCE; CHELATION THERAPY; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ERYTHROCYTE; FEMALE; FERRITIN BLOOD LEVEL; FLOW CYTOMETRY; HEART LEFT VENTRICLE MASS; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; JUVENILE; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PLATELET MICROPARTICLE; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCHOOL CHILD; SPLENECTOMY; THALASSEMIA MAJOR;

ADOLESCENT; BETA-THALASSEMIA; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; ERYTHROCYTES; FEMALE; FLOW CYTOMETRY; HEMOLYSIS; HUMANS; HYPERTENSION, PULMONARY; MALE; PLATELET ACTIVATION; RISK FACTORS; THROMBOSIS; VASCULAR STIFFNESS;

EID: 84878120250     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12108     Document Type: Article

References (78)

1. Weatherall DJ. The thalassemias. In: Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H, eds. The Molecular Basis of Blood Diseases, 3rd ed. Pennsylvania: W.B. Saunders Company; 2001:183-226.
2. Fucharoen S, Winichagoon P. Thalassemia and abnormal hemoglobin. Int J Hematol 2002;76(Suppl. 2):83-9.
3. Schrier SL. Pathophysiology of thalassemia. Curr Opin Hematol 2002;9:123-6.
4. Helley D, Eldor A, Girot R, Ducrocq R, Guillin MC, Bezeaud A. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia. Thromb Haemost 1996;76:322-7.
5. Pattanapanyasat K, Noulsri E, Fucharoen S, Lerdwana S, Lamchiagdhase P, Siritanaratkul N, Webster HK. Flow cytometric quantitation of red blood cell vesicles in thalassemia. Cytometry B Clin Cytom 2004;57:23-31.
6. Stoltz JF, Donner M. Hemorheology: importance of erythrocyte aggregation. Clin Hemorheol 1987;7:3-9.
7. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002;99:36-43.
8. Michaeli JM, Mittelman M, Grisaru D, Rachmilewitz EA. Thromboembolic complications in beta thalassemia major. Acta Haematol 1992;87:71-4.
9. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet J-M, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques. A role for apoptosis in plaque thrombogenicity. Circulation 1999;99:348-53.
10. Ramsey MW, Goodfellow J, Jones CJH, Luddington LA, Lewis MJ, Henderson AH. Endothelial control of arterial distensibility is impaired in chronic heart failure. Circulation 1995;92:3212-9.
11. Cheung YF, Chan GC, Ha SY. Arterial stiffness and endothelial function in patients with beta-thalassemia major. Circulation 2002;106:2561-6.
12. Aessopos A, Farmakis D, Tsironi M, Diamanti-Kandarakis E, Matzourani M, Fragodimiri C, Hatziliami A, Karagiorga M. Endothelial function and arterial stiffness in sickle-thalassemia patients. Atherosclerosis 2007;191:427-32.
13. O'Rourke M. Mechanical principles in arterial disease. Hypertension 1995;26:2-9.
14. Tsomi K, Karagiorga-Lagana M, Fragodimitri C, Karabatsos F, Katsiki V. Arterial elastorrhexis: manifestation of a generalized elastic tissue disorder in β-thalassemia major. Eur J Haematol 1999;63:287-94.
15. Aessopos A, Samarkos M, Voskaridou E, Papaioannou D, Tsironi M, Kavouklis E, Vaiopoulos G, Stamatelos G, Loukopoulos D. Arterial calcification in β-thalassemia. Angiology 1998;49:137-43.
16. Nichols WW, O'Rourke MF. Vascular impedance. In: McDonalds's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. 4th ed. London, UK: Edward Arnold 1998;54-97, 243-293.
17. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 2003;59:277-87.
18. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006;48:180-6.
19. Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003;1:1655-62.
20. Pattanapanyasat K, Gonwong S, Chaichompoo P, Noulsri E, Lerdwana S, Sukapirom K, Siritanaratkul N, Fucharoen S. Activated platelet-derived microparticles in thalassaemia. Br J Haematol 2007;136:462-71.
21. Habib A, Kunzelmann C, Shamseddeen W. Elevated levels of circulating procoagulant microparticles in patients with β-thalassemia intermedia. Haematologica 2008;93:941-2.
22. Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica 2009;94:1481-4.
23. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009;101:439-51.
24. Chen Y, Davis-Gorman G, Watson RR, McDonagh PF. Platelet CD62p expression and microparticle in murine acquired immune deficiency syndrome and chronic ethanol consumption. Alcohol Alcohol 2003;38:25-30.
25. Shigeta O, Kojima H, Jikuya T, Terada Y, Atsumi N, Sakakibara Y, Nagasawa T, Mitsui T. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation 1997;96:569-74.
26. Horigome H, Hiramatsu Y, Shigeta O, Nagasawa T, Matsui A. Overproduction of platelet microparticles in cyanotic congenital heart disease with polycythemia. J Am Coll Cardiol 2002;39:1072-7.
27. Sabatier F, Darmon P, Hugel B, et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002;51:2840-5.
28. Geiser T, Buck F, Meyer BJ, Bassetti C, Haeberli A, Gugger M. In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 2002;69:229-34.
29. Morris CR, Kim HY, Trachtenberg F, et al., Thalassemia Clinical Research Network. Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood 2011;118:3794-802.
30. Succar J, Musallam KM, Taher AT. Thalassemia and venous thromboembolism. Mediterr J Hematol Infect Dis 2011;3:e2011025.
31. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007;21:157-71.
32. Rautou PE, Vion AC, Amabile N, Chironi G, Simon A, Tedgui A, Boulanger CM. Microparticles, vascular function, and atherothrombosis. Circ Res 2011;109:593-606.
33. Wagner GM, Chiu DT-Y, Yee MC, Lubin BH. Red cell vesiculation-a common membrane physiologic event. J Lab Clin Med 1986;108:315-24.
34. Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG, Hack CE, Sturk A. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000;95:930-5.
35. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001;85:639-46.
36. Eldor A, Durst R, Hy-Am E, et al. A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood. Br J Haematol 1999;107:739-46.
37. Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003;115:721-8.
38. Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev 2008;22:283-92.
39. Cappellini MD, Motta I, Musallam KM, Taher AT. Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci 2010;1202:231-6.
40. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned MS, El-Chafic AH, Fasulo MR, Cappellini MD. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010;115:1886-92.
41. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program 2007;1:91-6.
42. Kuypers FA, Yuan J, Lewis RA, et al. Membrane phospholipid asymmetry in human thalassemia. Blood 1998;91:3044-51.
43. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L, Key NS, Hebbel RP. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003;102:2678-83.
44. Ardoin SP, Shanahan JC, Pisetsky DS. The role of microparticles in inflammation and thrombosis. Scand J Immunol 2007;66:159-65.
45. Vallar L, Regnault V, Latger-Cannard V, Lecompte T. Beta 2-glycoprotein I binding to platelet microparticle membrane specifically reduces immunoreactivity of glycoproteins IIb/IIIa. Thromb Haemost 2001;85:314-9.
46. Du ZD, Roguin N, Milgram E, Saab K, Koren A. Pulmonary hypertension in patients with thalassemia major. Am Heart J 1997;134:532-7.
47. McLaughlin VV, Archer SL, Badesch DB, et al. American College of Cardiology Foundation Task Force on Expert Consensus Documents: American Heart Association: American College of Chest Physicians: American Thoracic Society, Inc: Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619.
48. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008;359:2254-65.
49. Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006;81:858-63.
50. Machado RF, Gladwin MT. Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective. Chest 2010;137(Suppl. 6):30S-8S.
51. Anthi A, Machado RF, Jison ML, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med 2007;175:1272-9.
52. Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program 2008;2008:177-85.
53. Liem RI, Young LT, Thompson AA. Tricuspid regurgitant jet velocity is associated with hemolysis in children and young adults with sickle cell disease evaluated for pulmonary hypertension. Haematologica 2007;92:1549-52.
54. Singer ST, Kuypers FA, Styles L, Vichinsky EP, Foote D, Rosenfeld H. Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol 2006;81:670-5.
55. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000;111:467-73.
56. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Onpun S, Chuncharunee S, Thakkinstian A, Atamasirikul K. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients. Br J Haematol 2002;118:893-8.
57. Cappellini CD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. Coagulation and splenectomy: an overview. Ann N Y Acad Sci 2005;1054:317-24.
58. Kuypers FA, de Jong K. The role of phosphatidylserine in recognition and removal of erythrocytes. Cell Mol Biol (Noisy-le-grand) 2004;50:147-58.
59. Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, Cappellini MD. Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes. Br J Haematol 2001;112:48-50.
60. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood 2009;114:2861-8.
61. Vermylen C. What is new in iron overload? Eur J Pediatr 2008;167:377-81.
62. Silvilairat S, Sittiwangkul R, Pongprot Y, Charoenkwan P, Phornphutkul C. Tissue doppler echocardiography reliably reflects severity of iron overload in pediatric patients with beta thalassemia. Eur J Echocardiogr 2008;9:368-72.
63. Balla J, Vercellotti GM, Nath K, Yachie A, Nagy E, Eaton JW, Balla G. Haem, haem oxygenase and ferritin in vascular endothelial cell injury. Nephrol Dial Transplant 2003;18(Suppl. 5):v8-12.
64. Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, Taher A. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica 2011;96:1605-12.
65. Gardenghi S, Grady RW, Rivella S. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia. Hematol Oncol Clin North Am 2010;24:1089-107.
66. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-84.
67. Gardenghi S, Ramos P, Marongiu MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J Clin Invest 2010;120:4466-77.
68. Ramos P, Melchiori L, Gardenghi S, Van-Roijen N, Grady RW, Ginzburg Y, Rivella S. Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models. Ann N Y Acad Sci 2010;1202:24-30.
69. Banjerdpongchai R, Wilairat P, Fucharoen S, Bunyaratvej A. Morphological alterations and apoptosis of endothelial cells induced by thalassemic serum in vitro. Southeast Asian J Trop Med Public Health 1997;28(Suppl. 3):149-54.
70. Tsironi M, Aessopos A. The heart in sickle cell disease. Acta Cardiol 2005;60:589-98.
71. Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica 2007;92:658-65.
72. Aessopos A, Farmakis D, Trompoukis C, Tsironi M, Moyssakis I, Tsaftarides P, Karagiorga M. Cardiac involvement in sickle beta-thalassemia. Ann Hematol 2009;88:557-64.
73. Cheung YF. Arterial stiffness in the young: assessment, determinants, and implications. Korean Circ J 2010;40:153-62.
74. Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol 2011;47:1511-22.
75. Livera MA, Tesoriere L, Maggio A, D'Arpa D, Pintaudi AM, Pedone E. Oxidative modification of low-density lipoprotein and atherogenic risk in β-thalassemia. Blood 1998;10:3936-42.
76. Ulger Z, Aydinok Y, Gurses D, Levent E, Ozyurek AR. Stiffness of the abdominal aorta in beta-thalassemia major patients related with body iron load. J Pediatr Hematol Oncol 2006;28:647-52.
77. Tantawy AA, Adly AA, El Maaty MG, Amin SA. Subclinical atherosclerosis in young beta-thalassemia major patients. Hemoglobin 2009;33:463-74.
78. Hong YM. Atherosclerotic cardiovascular disease beginning in childhood. Korean Circ J 2010;40:1-9.